Observation on the Efficacy and Mechanism of SLIT With Dust Mite Allergen for PAR

• Status: Not yet recruiting
• Trial end date: 2024-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Allergic rhinitis is a common and recurrent ear, nose and throat (ENT) disease. It is a chronic or seasonal condition affecting 10% to 20% of the world's population. It is considered one of the most difficult diseases to treat globally and has become a major global health problem.

SUblingual immunotherapy (SIT) is currently considered to be an effective pairings therapy that can alter the natural progression of allergic rhinitis through immunomodulatory mechanisms. Immunotherapy is more suitable for patients with moderate to severe intermittent or persistent allergic rhinitis, especially for those with poor drug treatment. This treatment can significantly reduce the severity of allergic rhinitis, reduce the use of allergy medications, and improve the quality of life for many patients.

In the development of allergic rhinitis, the regulation of immune balance in Th1 / Th2 / Th17 cells is currently considered to be an important approach in the treatment of allergic rhinitis. But a growing body of evidence suggests that an intrinsic immune response is also the pathogenesis of allergic rhinitis. Innate lymphocytes are involved in mucosal immune formation, lymphocyte development, tissue damage repair and epithelial barrier protection, and play an important role in fighting infection, regulating inflammation and maintaining immune homeostasis. Three subsets of intrinsic lymphocytes (ILC1s, ILC2s, ILC3s) have been proposed to functionally approximate Th1, Th2, and Th17 in helper T lymphocytes (Th), but the results are inconclusive and the mechanism of ILCs role in AR progression is not fully elucidated.

Therefore, the purpose of this study was to investigate the efficacy and mechanism of subglossal immunotherapy for perennial allergic rhinitis, and to reveal the correlation between ILCs (ILC1s, ILC2s, ILC3s) and Th1 / Th2 / Th17 cell immunity, and to provide a basis for clinical studies of allergic rhinitis.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: People's Hospital of Anshun City of Guizhou Province
• Treatments: Antacids

Criteria

Inclusion Criteria:

1. Those who meet the above diagnostic criteria;

2. The course of disease is at least one year;

3. Over 18 years old to under 65 years old, both sexes;

4. Did not receive specific immunotherapy in the past 1 month or did not use any drugs for AR in the past 1 week;

5. Those with normal cognitive function agree to participate in this study and sign the informed consent form.

Exclusion Criteria:

1. Those who do not meet the above diagnostic and inclusion criteria;

2. Patients with severe nasal septum deviation, chronic rhinosinusitis, bronchial asthma, nasal polyps, upper respiratory tract infection, lung infection and other diseases;

3. Patients with severe dysfunction of heart, liver, kidney or autoimmune diseases;

4. pregnant or lactating women;

5. Allergic constitution and allergic to the experimental drugs and ingredients;

6. Patients with drug addiction history;

7. Patients with major neuropsychiatric diseases who cannot take medication regularly;

8. Patients who are participating in other clinical trials. Patients who met any of the above criteria were excluded.